Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

When the guide RNA recognizes and binds to the DNA segment ... The company reports that this patented technology is used in the gene therapy 'CASGEVY' developed by Vertex. CASGEVY is a treatment ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

UC Irvine scientists developed bioluminescent RNA tags, "tiny guiding lights," using luciferase to track RNA in real-time, ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

Despite that, the first RNA-targeting therapeutic in the market was launched only five years ago, and the vast majority of all Food and Drug Administration–approved drugs target proteins.

Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces market hurdles. However, recent political developments, including both at the White House and the Food and Drug ...

With over 750 million long RNA reads across 14 human cell lines, the Singapore Nanopore Expression (SG-NEx) dataset is designed to help researchers decode RNA complexity with greater precision ...

In Biology 101, we learn that RNA is a single, ribbon-like strand of base pairs that is copied from our DNA and then read like a recipe to build a protein. But there's more to the story.